1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > BioDelivery Sciences International, Inc. - Product Pipeline Review - 2015

BioDelivery Sciences International, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘BioDelivery Sciences International, Inc. - Product Pipeline Review - 2015’, provides an overview of the BioDelivery Sciences International, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioDelivery Sciences International, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BioDelivery Sciences International, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BioDelivery Sciences International, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the BioDelivery Sciences International, Inc.’s pipeline products

Reasons to buy

- Evaluate BioDelivery Sciences International, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BioDelivery Sciences International, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BioDelivery Sciences International, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BioDelivery Sciences International, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioDelivery Sciences International, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of BioDelivery Sciences International, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

BioDelivery Sciences International, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
BioDelivery Sciences International, Inc. Snapshot 5
BioDelivery Sciences International, Inc. Overview 5
Key Information 5
Key Facts 5
BioDelivery Sciences International, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
BioDelivery Sciences International, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
BioDelivery Sciences International, Inc. - Pipeline Products Glance 12
BioDelivery Sciences International, Inc. - Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
BioDelivery Sciences International, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
BioDelivery Sciences International, Inc. - Drug Profiles 16
fentanyl citrate 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
clonidine hydrochloride 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
BEMA Triptan 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
buprenorphine hydrochloride depot 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
BioDelivery Sciences International, Inc. - Pipeline Analysis 21
BioDelivery Sciences International, Inc. - Pipeline Products by Target 21
BioDelivery Sciences International, Inc. - Pipeline Products by Route of Administration 22
BioDelivery Sciences International, Inc. - Pipeline Products by Molecule Type 23
BioDelivery Sciences International, Inc. - Pipeline Products by Mechanism of Action 24
BioDelivery Sciences International, Inc. - Recent Pipeline Updates 25
BioDelivery Sciences International, Inc. - Company Statement 28
BioDelivery Sciences International, Inc. - Locations And Subsidiaries 32
Head Office 32
Other Locations and Subsidiaries 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables
BioDelivery Sciences International, Inc., Key Information 5
BioDelivery Sciences International, Inc., Key Facts 5
BioDelivery Sciences International, Inc. - Pipeline by Indication, 2015 7
BioDelivery Sciences International, Inc. - Pipeline by Stage of Development, 2015 8
BioDelivery Sciences International, Inc. - Monotherapy Products in Pipeline, 2015 9
BioDelivery Sciences International, Inc. - Out-Licensed Products in Pipeline, 2015 10
BioDelivery Sciences International, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 11
BioDelivery Sciences International, Inc. - Pre-Registration, 2015 12
BioDelivery Sciences International, Inc. - Phase III, 2015 13
BioDelivery Sciences International, Inc. - Preclinical, 2015 14
BioDelivery Sciences International, Inc. - Discovery, 2015 15
BioDelivery Sciences International, Inc. - Pipeline by Target, 2015 21
BioDelivery Sciences International, Inc. - Pipeline by Route of Administration, 2015 22
BioDelivery Sciences International, Inc. - Pipeline by Molecule Type, 2015 23
BioDelivery Sciences International, Inc. - Pipeline Products by Mechanism of Action, 2015 24
BioDelivery Sciences International, Inc. - Recent Pipeline Updates, 2015 25
BioDelivery Sciences International, Inc., Subsidiaries 32

List of Figures
BioDelivery Sciences International, Inc. - Pipeline by Top 10 Indication, 2015 7
BioDelivery Sciences International, Inc. - Pipeline by Stage of Development, 2015 8
BioDelivery Sciences International, Inc. - Monotherapy Products in Pipeline, 2015 9
BioDelivery Sciences International, Inc. - Pipeline by Top 10 Target, 2015 21
BioDelivery Sciences International, Inc. - Pipeline by Top 10 Route of Administration, 2015 22
BioDelivery Sciences International, Inc. - Pipeline by Top 10 Molecule Type, 2015 23
BioDelivery Sciences International, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.